Sign in
PLYX Stock Price, Chart, Stats & News
Polaryx Therapeutics, Inc. Common Stock
Save
Polaryx Therapeutics, Inc. Common Stock (PLYX) does not currently pay a dividend.
115.64M
Market cap
–
Current P/E
–
Forward P/E
PLYX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -165.77% |
ROE | -206.96% |
D/E | – |
Interest coverage ratio | – |
PLYX valuation
P/E | – |
P/S | – |
P/B | 80.79x |
P/CF | -93.46x |
P/FCF | -93.15x |
P/OCF | -93.46x |
PEG | 0.65x |
EV multiple | -47.65x |
About
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations.
Similar securities
Based on sector and market capitalization
Report issue